Tenofovir hydrate

• CAT Number: I002586
• CAS Number: 206184-49-8
• Molecular Formula: C9H16N5O5P
• Molecular Weight: 305.23
• Purity: ≥95%
• Synonyms: [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid;hydrate
• Target: HIV
• Solubility: 10 mM in DMSO
• Storage: Store at -20C
• IC50: 0.5-2.2 uM (HIV-1); 1.6-4.9 uM (HIV-2) [1]
• InChI: InChI=1S/C9H14N5O4P.H2O/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14;/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17);1H2/t6-;/m1./s1
• InChIKey: PINIEAOMWQJGBW-FYZOBXCZSA-N
• SMILES: C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O.O

Tenofovir hydrate（Cat No.:I002586）is a nucleotide reverse transcriptase inhibitor (NRTI) used extensively in antiviral research, particularly against HIV and hepatitis B virus. This compound interferes with viral DNA synthesis by acting as a chain terminator during replication, making it a cornerstone in studying viral replication mechanisms. Tenofovir hydrate is also crucial in evaluating resistance mutations and drug efficacy in antiviral therapy development. With its stability and efficacy, Tenofovir hydrate supports research aimed at understanding nucleoside analog pharmacology and improving therapeutic strategies for chronic viral infections.

Reference

[1]. http://www.immunopaedia.org.za/fileadmin/new_all/case_studies/pdfs/tenofovir.pdf
[2]. Witvrouw M, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004 Feb;9(1):57-65.
[3]. Ying C, et al. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir,tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat. 2000 Mar;7(2):161-5.
[4]. Wainberg MA, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther. 1999;4(2):87-94.
[5]. De Clercq E, et al. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev. 2003 Oct;16(4):569-96.
[6]. Woratanarat K, et al. Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study. J Med Assoc Thai. 2013 Apr;96(4):432-9.